Therapies with diverse mechanisms of action kill cells by a similar exponential process in advanced cancers

Cancer Research

Volumn 74, Issue 17, 2014, Pages 4653-4662

  Blagoev, Krastan B ^a,b   Wilkerson, Julia ^c   Stein, Wilfred D ^c,d   Yang, James ^c   Bates, Susan E ^c   Fojo, Tito ^c  

^a NATIONAL SCIENCE FOUNDATION   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ANIMAL; BIOLOGICAL MODEL; CELL DEATH; DRUG EFFECTS; HUMAN; KINETICS; NEOPLASMS; PATHOLOGY; PHYSIOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL DEATH; HUMANS; KINETICS; MODELS, BIOLOGICAL; NEOPLASMS;

EID: 84907053832     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-0420     Document Type: Article

References (21)

1. Skipper HE. Perspectives in cancer chemotherapy: therapeutic design. Cancer Res 1964;24:1295-302.
2. Skipper HE. Laboratory models: some historical perspective. Cancer Treat Rep 1986;70:3-7.
3. Powell AA, Talasaz AH, Zhang H, Coram MA, Reddy A, Deng G, et al. Single cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell lines. PLoS ONE 2012;7: e33788.
4. Stein WD, Figg WD, Dahut W, Stein AD, Hoshen MB, Price D, et al. Tumor growth rates derived from data for patients in a clinical trial correlate strongly with patient survival: a novel strategy for evaluation of clinical trial data. Oncologist 2008;13:1046-54.
5. Stein WD, Gulley JL, Schlom J, Madan RA, Dahut W, Figg WD, et al. Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as anindicator of therapeutic efficacy. Clin Cancer Res 2011;17:907-17.
6. Stein WD, Huang H, Menefee M, Edgerly M, Kotz H, Dwyer A, et al. Other paradigms: growth rate constants and tumor burden determined using computed tomography data correlate strongly with the overall survival of patients with renal cell carcinoma. Cancer J 2009;15:441-7.
7. Stein WD, Wilkerson J, Kim ST, Huang X, Motzer RJ, Fojo AT, et al. Analyzing the pivotal trial that compared sunitinib and IFN-a in renal cell carcinoma, using a method that assesses tumor regression and growth. Clin Cancer Res 2012;18:2374-81.
8. Stein WD, Yang J, Bates SE, Fojo T. Bevacizumab reduces the growth rate constants of renal carcinomas: a novel algorithm suggests early discontinuation of bevacizumab resulted in a lack of survival advantage. Oncologist 2008;13:1055-62.
9. Dahut WL, Gulley JL, Arlen PM, Liu Y, Fedenko KM, Steinberg SM, et al. Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol 2004;22:2532-9.
10. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349:427-34.
11. Ning YM, Gulley JL, Arlen PM, Woo S, Steinberg SM, Wright JJ, et al. Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 2010;28:2070-6.
12. Thomas ES, Gomez HL, Li RK, Chung HC, Fein LE, Chan VF, et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 2007; 25:5210-7.
13. Orlowski RZ, Nagler A, Sonneveld P, Bladé J, Hajek R, Spencer A, et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol 2007;25:3892-901.
14. Figg WD, Liu Y, Arlen P, Gulley J, Steinberg SM, Liewehr DJ, et al. A randomized, phase II trial of ketoconazole plus alendronate versus ketoconazole alone in patients with androgen independent prostate cancer and bone metastases. J Urol 2005;173:790-6.
15. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon α in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115-24.
16. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, et al. Overall survival and updated results for sunitinib compared with interferon α in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27:3584-90.
17. Wells SA Jr, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, et al. J Clin Oncol 2012;30:134-41.
18. Krane K. Introductory nuclear physics. New York, New York: John Wiley & Sons Inc., 1988.
19. Frank SA. In: Dynamics of cancer: incidence, inheritance, and evolution. Princeton, NJ: Princeton University Press, 2007.
20. Kohanski MA, Dwyer DJ, Hayete B, Lawrence CA, Collins JJ. A common mechanism of cellular death induced by bactericidal antibiotics. Cell 2007;130:797-810.
21. Stein WD. Analysis of cancer incidence data on the basis of multistage and clonal growth models. Adv Cancer Res 1991;56: 161-213.